6,708 press releases indexed under saas.
Nemotron 3, Gemma 4, cotomi, Qwen3.7-Max, and GLM-5.2 Validated to Run on VMware Cloud Foundation Nemotron 3, Gemma 4, cotomi, Qwen3.7-Max, and GLM-5.2 Validated to Run on VMware Cloud Foundation
Dito collaborates with Wiz, now part of Google Cloud, to protect everything customers build and run. RESTON, Va., Aug. 31, 2026 /PRNewswire-PRWeb/ -- Dito, a Premier Google Cloud Co-Sell, Services, and Technology Partner and enterprise security integrator, today announced it has joined...
NEW YORK, NY - August 31, 2026 ( NEWMEDIAWIRE ) - tZERO Group, Inc. (“tZERO”), a leader in blockchain-powered financial infrastructure, and Intercontinental Exchange, Inc. (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets, today announced a set of agreements to support tokenized securities markets. The firms agreed a Memorandum of Understanding (the “MOU”) regarding tZERO’s role as a premier design partner in developing digital transfer agent and broker-dealer infrastructure intended to support on-chain settlement of tokenized securities transactions on ICE’s upcoming NYSE-affiliated tokenized securities platform (the Digital Trading Platform). ICE has also agreed to make an investment in tZERO’s latest financing round
Singapore technology company in Riyadh to explore extending Robin AI's food-compliance capabilities across ASEAN and MENA SINGAPORE and RIYADH, Saudi Arabia, Aug. 31, 2026 /PRNewswire/ -- Singapore-founded technology company Smobler is exploring the expansion of Robin AI, a platform...
New LLM-agnostic capability connects Research Desk with AI tools including Claude and ChatGPT, giving researchers and developers new ways to work with the platform NEW ORLEANS, Aug. 31, 2026 /PRNewswire/ -- Rep Data, the data quality leader for the market research industry, has launched...
Transit-Adjacent Mid-Rise Apartments Part of Master Planned Mixed-Use Community CHEVY CHASE, Md., Aug. 31, 2026 /PRNewswire/ -- FCP® announces a $22 million preferred equity investment through its Structured Investments platform to support the development of a 305-unit, seven-story...
Patent covers synergistic use of Ampligen with pembrolizumab across cancer indications, including pancreatic, ovarian, colorectal, breast, lung and other cancers, reinforcing the potential breadth and long-term value of AIM’s oncology platform Patent covers synergistic use of Ampligen with pembrolizumab across cancer indications, including pancreatic, ovarian, colorectal, breast, lung and other cancers, reinforcing the potential breadth and long-term value of AIM’s oncology platform
(PR-inside.com) Company Advances Beyond Public Cancer Imaging Datasets With First Real-World User-Submitted Testing Phase MESA, AZ / ACCESS Newswire / August 31, 2026 / Medical Care Technologies Inc. (OTCID:MDCE) today announced that its MDCE Melanoma Scan Beta platform is seeking its first set of volunteers for human-submitted dataset testing - a significant step beyond the Company's prior work training and evaluating models solely on established public cancer imaging datasets. Until now, development of MDCE Melanoma Scan Beta has centered on structured internal testing and AI model optimization using gold-standard public dermatology resources, including HAM10000, ISIC Archive collections, and TCIA melanoma cohorts. The move ..
The agentic AI video platform is designed to autonomously create and distribute short-form videos at scale for podcasters and social media influencers The agentic AI video platform is designed to autonomously create and distribute short-form videos at scale for podcasters and social media influencers
OneMedNet’s iRWD Platform Enables Rapid Feasibility-to-Delivery for Leading AI-Driven Drug Development Company
ROCKVILLE, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Professional snowboarder, Chloe Kim, is partnering with Supernus Pharmaceuticals as a compensated ambassador to discuss her journey with attention-deficit/hyperactivity disorder (ADHD) and her treatment plan with Qelbree (viloxazine extended-release capsules), a once-daily, non-stimulant medication for patients 6 years and older. Designed for flexible once-a-day routine integration, Qelbree offers 24-hour medication exposure, no evidence of abuse potential, and versatile administration options, including the ability to be sprinkled and taken at any time of day (either morning or night). Through this partnership, Chloe Kim will open up about her own diagnosis to challenge misconceptions about ADHD. By sharing her lived experience, she will e
NVIDIA and MediaTek today announced a deepening of their longstanding collaboration to build the next generations of AI computing platforms — spanning AI infrastructure, local AI computing and automotive.